Other analysts have cautioned against putting too much stock in the rate of dropouts, arguing that clinical trial designs do not fully reflect how the drug may be used in practice, including more flexible dosing and patient selection
Sever'yanova L, Dolgintsev ME
doi: 10.1016/j.amjms.2019.09.002 128 PapadopoulosPDTsigalouCValsamakiPNKonstantinidisTGVoidarouCBezirtzoglouE
J Invest Dermatol 130:17851796 Hogan AE, Tobin AM, Ahern T et al (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells-lessons from obesity, diabetes and psoriasis
The key variables are temperature, light exposure, and moisture protection
If the doctor only says eat less, move more, ask: How are we evaluating metabolism and genetics? On GLP-1s